Skip to main content

Table 4 Adjusted HR (95% CI) for adverse cardiovascular outcomes per 1-SD increase of FPG and 2 h-PCPG. (n = 408)

From: Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study

  CVD Hard CVD CHD Hard CHD
HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
FPG
 Model 1 1.21 (1.09–1.34)  < 0.001 1.27 (1.08–1.49) 0.004 1.15 (1.03–1.29) 0.01 1.22 (0.99–1.49) 0.06
 Model 2 1.20 (1.08–1.34) 0.001 1.27 (1.07–1.51) 0.006 1.15 (1.02–1.29) 0.02 1.25 (1.00–1.56) 0.05
2 h-PCPG
 Model 1 1.21 (1.08–1.36) 0.001 1.21 (1.01–1.45) 0.04 1.17 (1.03–1.32) 0.01 1.20 (0.96–1.51) 0.11
 Model 2 1.21 (1.07–1.36) 0.002 1.21 (0.99–1.47) 0.06 1.16 (1.03–1.32) 0.02 1.23 (0.96–1.57) 0.10
  1. CVD cardiovascular disease, CHD coronary heart disease, HR hazard ratio, CI confidence interval, FPG fasting plasma glucose, 2 h-PCPG 2 h post challenge plasma glucose
  2. Model 1: age and sex
  3. Model 2: model 1 + body mass index, current smoking, family history of premature CVD, hypertension, hypercholesterolemia, low HDL-C, heart rate, use of aspirin, use of beta blockers and low physical activity